Navigation Links
Cell Transplantation reports consistent and successful islet isolations offer diabetes hope
Date:6/3/2010

Tampa, Fla. (June 3, 2010) A team of researchers from several collaborating Baylor University research centers and from Japan's Okayama Graduate School of Medicine have found a way to more consistently isolate pancreatic islet cells from brain dead donors using ductal injection (DI), a process that immediately cools donor islet cells at the injection site. The more successful islet isolation process resulted in the three type 1-diabetes patients, who received islet cell transplants, becoming insulin independent.

Their study is published in issue 19(3) of Cell Transplantation and it is now freely available on-line at http://www.ingentaconnect.com/content/cog/ct/ .

"Inconsistent islet isolation is one of the important issues in clinical islet transplantation," said Dr. Shinichi Matsumoto, the research team's lead author. "Failure of donor islet isolation often results from the loss of the donor pancreas. Our simple modification of the retrieval process appears valuable for assuring greater success in islet transplantation."

Ductal injection is a procedure that modifies the islet isolation process using a cooling solution on the pancreatic islet cells derived from brain-dead donors. The cooling solution, applied at the donor's pancreatic ductal site, aids the viability of the islet cells.

The team successfully isolated islet cells in the DI group seven times while only three out of eight islet cell groups were isolated in the nonductal injection group. When islets from the DI group were transplanted into three type 1 diabetic patients, all three became insulin independent.

"DI significantly improved the quantity and quality of isolated islets and resulted in a high success rate of clinical islet transplantation," said Dr. Matsumoto.

According to the research team, a fifty percent success rate for clinical islet isolation has been standard; they were able to achieve a better than 80 percent success rate using DI.

The team reported that there were no significant demographic or clinical differences in the two patient groups receiving islet transplants, nor were there significant differences in the donated pancreata. All donor pancreata were preserved for less than six hours. Each patient received two islet preparations.

"In the DI group, the fasting blood glucose of all three patients improved after a single islet transplantation, and improved further after the second transplantation," commented Dr. Matsumoto. "None of these patients experienced subsequent hypoglycemia, and all three became insulin independent."

The team had recently shown that the DI process was successful in animal models because DI prevented tissue and cell death, suggesting that DI improved the quality and quantity of the isolated islet cells destined for transplantation.

"The number of islets isolated from donor pancreata continues to be quite variable and many times are not sufficient for clinical transplantation" said Dr. Rodolfo Alejandro, section editor for Cell Transplantation and Professor of Medicine at the University of Miami Miller School of Medicine. "This paper describes a novel approach to improve islet isolation yields. These are promising results that need to be confirmed in a randomized concurrent protocol".


'/>"/>

Contact: David Eve
celltransplantation@gmail.com
Cell Transplantation Center of Excellence for Aging and Brain Repair
Source:Eurekalert

Related biology news :

1. Novel Parkinsons treatment strategy involves cell transplantation
2. Rare genetic disease successfully reversed using stem cell transplantation
3. Ovarian transplantation: First baby is born after a new technique
4. Ovarian transplantation: New technique gives greatly improved results in this delicate operation
5. REGiMMUNE presents enhanced efficacy data in preclinical transplantation models
6. New book includes advances in the science and practice of transfusion and transplantation
7. Embryonic stem cells might help reduce transplantation rejection
8. Researchers discover link between organ transplantation and increased cancer risk
9. Stem-cell transplantation improves muscles in MD animal model, UT Southwestern researchers report
10. Clearance of hepatitis C viral infection after liver transplantation
11. New climate change reports underscore need for action
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
(Date:3/29/2016)... Florida , March 29, 2016 ... the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased ... in ink used in a variety of writing instruments, ... Buyers of originally created collectibles from athletes on LegacyXChange ... forensic analysis of the DNA. Bill ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... Brooklyn, NY (PRWEB) , ... June 24, 2016 , ... ... 15mm, machines such as the Cary 5000 and the 6000i models are higher end ... height is the height of the spectrophotometer’s light beam from the bottom of the ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
Breaking Biology Technology: